C1-inhibitor

The Worldwide Antiviral Therapeutics Industry is Expected to Reach $100 Billion by 2027 at a 8.35% CAGR - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023

The Global Antiviral Therapeutics Market is estimated to be USD 67.54 Bn in 2022 and expected to reach USD 100.86 Bn by 2027, growing at a CAGR of 8.35%.

Key Points: 
  • The Global Antiviral Therapeutics Market is estimated to be USD 67.54 Bn in 2022 and expected to reach USD 100.86 Bn by 2027, growing at a CAGR of 8.35%.
  • Market dynamics are forces that impact the prices and behaviors of the Global Antiviral Therapeutics Market stakeholders.
  • The report presents a detailed Ansoff matrix analysis for the Global Antiviral Therapeutics Market.
  • By Drug, the market is classified into Hepatitis Antiviral Drug, Herpes Antiviral Drug, HIV Antiviral Drug, and Influenza Antiviral Drug.

Global Hemoglobinopathies Market Report 2022: Growth of Tissue-Oriented, Safe, and Efficient Gene Editing Technology Bolsters Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023

The Global Hemoglobinopathies Market size is expected to reach $6.0 billion by 2028, rising at a market growth of 5.6% CAGR during the forecast period.

Key Points: 
  • The Global Hemoglobinopathies Market size is expected to reach $6.0 billion by 2028, rising at a market growth of 5.6% CAGR during the forecast period.
  • The growth of tissue-oriented, safe, and efficient gene editing technology has contributed to the development of various gene therapy types for hemoglobin-related illnesses.
  • Region-wise, the hemoglobinopathies market is analyzed across North America, Europe, Asia Pacific, and LAMEA.
  • The North America region acquired the largest revenue share in the hemoglobinopathies market in 2021.

Global Antiviral Drugs Market Report 2022: A New Approach to Developing Antiviral Drugs Could Slow Future Viral Outbreaks and Save Lives - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022

Growing Occurrence of Viral Diseases Such as HIV, Hepatitis, and Influenza

Key Points: 
  • Growing Occurrence of Viral Diseases Such as HIV, Hepatitis, and Influenza
    The Global Antiviral Drugs Market is segmented based on Drug Type, Therapeutics, and Geography.
  • By Drug Type, the market is classified into DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, and Others.
  • By Therapeutics, the market is classified into HIV/Aids Therapeutics, Hepatitis (B & C) Therapeutics, Herpes Therapeutics, Influenza Therapeutics, and Pneumonia.
  • The report presents a detailed Ansoff matrix analysis for the Global Antiviral Drugs Market.

Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, November 10, 2022

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) --  Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today reported financial results for the third quarter ended September 30, 2022, and provided recent business highlights. 

Key Points: 
  • The third quarter was a turning point for Immuneering as we submitted and cleared our first IND.
  • IND Cleared for Phase 1/2a Trial of IMM-1-104 in September 2022; Clinical Trial (NCT05585320) is Recruiting, and First Patient is Expected to be Dosed this Quarter.
  • On September 30, 2022, the company announced its IND application for IMM-1-104 had been cleared.
  • The Phase 1/2a clinical trial is now recruiting and the company intends to dose its first patient this quarter.

Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation

Retrieved on: 
Tuesday, November 8, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced financial results and recent highlights for the third quarter ended September 30, 2022.

Key Points: 
  • Presented at Discovery on Target 2022 held October 17-20, 2022, on HBV core inhibitors for the treatment of chronic viral infection.
  • Mr. Okazaki and William Delaney, PhD, chief scientific officer, presented during the H.C. Wainwright 3rd Annual HBV Virtual Conference held October 18, 2022.
  • Dr. McHutchison presented during the H.C. Wainwright 24th Annual Global Investment Conference held September 12-14, 2022.
  • Cash, cash equivalents and marketable securities were $108.7 million as of September 30, 2022, compared to $128.6 million as of June 30, 2022.

THE CANADIAN INFLAMMATORY BOWEL DISEASE RESEARCH CONSORTIUM AWARDS FIRST $1M PIONEER GRANT FROM TAKEDA CANADA

Retrieved on: 
Tuesday, November 8, 2022

Funding will support the first active comparator, multicentre, randomized trial to evaluate optimal first-line treatment strategy for Ileal Crohn's disease

Key Points: 
  • Funding will support the first active comparator, multicentre, randomized trial to evaluate optimal first-line treatment strategy for Ileal Crohn's disease
    TORONTO, Nov. 8, 2022 /CNW/ - The Canadian Inflammatory Bowel Disease Research Consortium (CIRC) awards the inaugural $1 million PIONEER Grant from Takeda Canada Inc. (Takeda), in support of high-quality, impactful Canadian clinical research to improve patient outcomes and quality of life for people living with inflammatory bowel disease (IBD).
  • The grant awardee will also receive assistance from Alimentiv, a world-class research organization with deep expertise in conducting clinical trials in IBD, through expertise, research execution and in-kind support.
  • Ileal CD increases the risk for bowel damage so choosing the right medical treatment is critical for preventing complications like hospitalization and surgery.
  • "At Takeda, we are committed to advancing scientific research in the area of IBD and are proud to establish the CIRC PIONEER Grant to support Canadian researchers in their pursuit of life-changing innovations," said Rute Fernandes, General Manager, Takeda Canada.

Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

Retrieved on: 
Friday, November 4, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported clinical and preclinical data from its virology portfolio at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®. The new data are being presented at the conference as part of four poster presentations, including two late breaker presentations.

Key Points: 
  • The new data are being presented at the conference as part of four poster presentations, including two late breaker presentations.
  • The data presented at AASLDs The Liver Meeting demonstrate the significant progress that we are making in advancing and broadening our early-stage virology programs.
  • We remain committed to our goal of discovering and developing novel antivirals that change the treatment paradigm for serious viral diseases.
  • Unlike core inhibitors or entecavir, these compounds inhibit HBsAg production whether administered before infection or after the establishment of cccDNA.

VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients

Retrieved on: 
Wednesday, October 12, 2022

Given this potential synergy, we are excited to be partnering with Agenus in this clinical collaboration.

Key Points: 
  • Given this potential synergy, we are excited to be partnering with Agenus in this clinical collaboration.
  • Balstilimab is a promising anti-PD-1 therapy that has been studied in over 750 patients.
  • Combining balstilimab with VBIs vaccine enhances innate and adaptive anti-tumor immunity and may offer promise to patients with GBM, an aggressive and difficult to treat cancer.
  • Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.

VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients

Retrieved on: 
Wednesday, October 12, 2022

Given this potential synergy, we are excited to be partnering with Agenus in this clinical collaboration.

Key Points: 
  • Given this potential synergy, we are excited to be partnering with Agenus in this clinical collaboration.
  • Balstilimab is a promising anti-PD-1 therapy that has been studied in over 750 patients.
  • Combining balstilimab with VBIs vaccine enhances innate and adaptive anti-tumor immunity and may offer promise to patients with GBM, an aggressive and difficult to treat cancer.
  • Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data for Baxdrostat in Treatment-Resistant Hypertension at the Upcoming 2022 American Heart Association Scientific Sessions

Retrieved on: 
Wednesday, September 28, 2022

Baxdrostat is a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase.

Key Points: 
  • Baxdrostat is a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase.
  • Results From a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients with Treatment-Resistant Hypertension
    Please visit the AHA Scientific Sessions Late-Breaking Science for the most current programming.
  • CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases.
  • Though often asymptomatic, hypertension significantly increases the risk of heart disease, stroke and kidney disease, amongst other diseases.